Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma - PubMed (original) (raw)
Case Reports
. 2014 Jan 1;134(1):102-13.
doi: 10.1002/ijc.28338. Epub 2013 Jul 16.
Affiliations
- PMID: 23784959
- DOI: 10.1002/ijc.28338
Case Reports
Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma
Ana B del Campo et al. Int J Cancer. 2014.
Abstract
Cancer cells escape T-cell-mediated destruction by losing human leukocyte antigen (HLA) class I expression via various mechanisms, including loss of beta2-microglobulin (β2m). Our study illustrates the immune escape of HLA class I-negative tumor cells and chronological sequence of appearance of tumor β2m gene mutation in successive lesions obtained from a patient with metastatic melanoma. We observed a gradual decrease in HLA expression in consecutive lesions with few HLA-negative nodules in the primary tumor and the emergence of a totally negative lesion at later stages of the disease. We detected loss of β2m in β2m-negative nests of the primary tumor caused by a combination of two alterations: (i) a mutation (G to T substitution) in codon 67 in exon 2 of β2m gene, producing a stop codon and (ii) loss of the second gene copy by loss of heterozygosity (LOH) in chromosome 15. The same β2m mutation was found in a homogeneously β2m-negative metastasis 10 months later and in a cell line established from a biopsy of a postvaccination lymph node. Microsatellite analysis revealed the presence of LOH in chromosomes 6 and 15 in tumor samples, showing an accumulation of chromosomal loss at specific short tandem repeats in successive metastases during disease progression. HLA loss correlated with decreased tumor CD8+ T-cell infiltration. Early incidence of β2m defects can cause an immune selection and expansion of highly aggressive melanoma clones with irreversible genetic defects causing total loss of HLA class I expression and should be taken into consideration as a therapeutic target in the development of cancer immunotherapy protocols.
Keywords: beta2-microglobulin mutation; immune escape; metastatic melanoma; tumor HLA class I loss.
© 2013 UICC.
Similar articles
- The coincidence of chromosome 15 aberrations and beta2-microglobulin gene mutations is causative for the total loss of human leukocyte antigen class I expression in melanoma.
Paschen A, Arens N, Sucker A, Greulich-Bode KM, Fonsatti E, Gloghini A, Striegel S, Schwinn N, Carbone A, Hildenbrand R, Cerwenka A, Maio M, Schadendorf D. Paschen A, et al. Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3297-305. doi: 10.1158/1078-0432.CCR-05-2174. Clin Cancer Res. 2006. PMID: 16740750 - beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma.
Hicklin DJ, Wang Z, Arienti F, Rivoltini L, Parmiani G, Ferrone S. Hicklin DJ, et al. J Clin Invest. 1998 Jun 15;101(12):2720-9. doi: 10.1172/JCI498. J Clin Invest. 1998. PMID: 9637706 Free PMC article. - Complete loss of HLA class I antigen expression on melanoma cells: a result of successive mutational events.
Paschen A, Méndez RM, Jimenez P, Sucker A, Ruiz-Cabello F, Song M, Garrido F, Schadendorf D. Paschen A, et al. Int J Cancer. 2003 Mar 1;103(6):759-67. doi: 10.1002/ijc.10906. Int J Cancer. 2003. PMID: 12516095 - Implication of the β2-microglobulin gene in the generation of tumor escape phenotypes.
Bernal M, Ruiz-Cabello F, Concha A, Paschen A, Garrido F. Bernal M, et al. Cancer Immunol Immunother. 2012 Sep;61(9):1359-71. doi: 10.1007/s00262-012-1321-6. Epub 2012 Jul 26. Cancer Immunol Immunother. 2012. PMID: 22833104 Free PMC article. Review. - Beta2-microglobulin gene mutations in human melanoma cells: molecular characterization and implications for immune surveillance.
Hicklin DJ, Dellaratta DV, Kishore R, Liang B, Kageshita T, Ferrone S. Hicklin DJ, et al. Melanoma Res. 1997 Aug;7 Suppl 2:S67-74. Melanoma Res. 1997. PMID: 9578419 Review.
Cited by
- IL-2-armored peptide-major histocompatibility class I bispecific antibodies redirect antiviral effector memory CD8+ T cells to induce potent anti-cancer cytotoxic activity with limited cytokine release.
Schardt JS, Walseng E, Le K, Yang C, Shah P, Fu Y, Alam K, Kelton CR, Gu Y, Huang F, Lin J, Liu W, Dippel A, Zhang H, Mulgrew K, Pryts S, Chennupati V, Chen HC, Denham J, Chen X, Pradhan P, Wu Y, Hardman C, Zhao C, Kierny M, Song Y, Dovedi SJ, Cemerski S, Mazor Y. Schardt JS, et al. MAbs. 2024 Jan-Dec;16(1):2395499. doi: 10.1080/19420862.2024.2395499. Epub 2024 Aug 28. MAbs. 2024. PMID: 39205483 Free PMC article. - Immune Evasion Through Human Leukocyte Antigen Implications and Its Impact on Targeted Therapy.
Andreescu M, Andreescu B. Andreescu M, et al. Cureus. 2024 Jan 22;16(1):e52737. doi: 10.7759/cureus.52737. eCollection 2024 Jan. Cureus. 2024. PMID: 38384647 Free PMC article. Review. - Primary and acquired resistance to first-line therapy for clear cell renal cell carcinoma.
Astore S, Baciarello G, Cerbone L, Calabrò F. Astore S, et al. Cancer Drug Resist. 2023 Aug 2;6(3):517-546. doi: 10.20517/cdr.2023.33. eCollection 2023. Cancer Drug Resist. 2023. PMID: 37842234 Free PMC article. Review. - A luminescence-based method to assess antigen presentation and antigen-specific T cell responses for in vitro screening of immunomodulatory checkpoints and therapeutics.
Álvarez Freile J, Qi Y, Jacob L, Lobo MF, Lourens HJ, Huls G, Bremer E. Álvarez Freile J, et al. Front Immunol. 2023 Jul 25;14:1233113. doi: 10.3389/fimmu.2023.1233113. eCollection 2023. Front Immunol. 2023. PMID: 37559730 Free PMC article. - A novel cell-based screen identifies chemical entities that reverse the immune-escape phenotype of metastatic tumours.
Nohara LL, Ellis SLS, Dreier C, Dada S, Saranchova I, Bok Choi K, Munro L, Al Haddad E, Pfeifer CG, Coyle KM, Morrice JR, Shim DJS, Ahn P, De Voogd N, Williams DE, Cheng P, Garrovillas E, Andersen RJ, Jefferies WA. Nohara LL, et al. Front Pharmacol. 2023 May 15;14:1119607. doi: 10.3389/fphar.2023.1119607. eCollection 2023. Front Pharmacol. 2023. PMID: 37256225 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials